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and 11.7%, respectively. Age had a signiﬁcant inﬂuence on survival and on time to the ﬁrst tumor progression, whereas extent
of surgery in the initial therapy did not.
Conclusion. We conclude that these patients can expect a median survival of over 2 years and that young age have a positive
inﬂuence on survival, and that salvage therapies can extend survival after the onset of tumor progression for nearly a year.
http://dx.doi.org/10.1016/j.rpor.2013.03.128
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Patients and methods. We have analyzed the clinical course of 49 patients who underwent initial microsurgery tumor resection
and implantation carmustine-containing wafers into the resection cavity. Time period ranged from 2003 to 2012. Forty-nine
were included (18 females and 31 males) with a mean age of 53.3 years. First symptom mots common: motor impairment 49.9%.
Histology was conﬁrmed as glioblastoma in 91.8%, anaplastic astrocytoma, 6.1%. Karnofsky performance status (KPS) was 100
in 73.5%, 90 in 22.4% and 80 in 4.1%. Surgery was reported as gross total resection in 85.7% and parcial resection in 14.3%. 46.2%
of patients were treated using carmustine wafers followed by standard radiotherapy (RT) with concomitant and adjuvant temo-
zolomide (TMZ); 51.3%, carmustine wafers and RT with adjuvant TMZ; 2.6%, carmustine wafers and RT with concomitant TMZ.
45.8% patients do not completed treatment. Reasons for discontinuation were progression (86.4%) and adverse events (13.6%).
Results. After a median follow-up of 84 months, 81.3% progressed and 83.3% died. One, two and three year OS rates were 60.5%,
21.3%, 13.3% respectively, and four, ﬁve, six and seven year rates were 10.7%. Mean OS was 21.83 months (95% CI, 14.9–28.8) and
median OS was 15 months (95% CI, 11.8–18.2). One, two, three year PFS rates were 30.8%, 5.1%, 2.6% respectively, and four, ﬁve,
six and seven year rates were 0%. Mean PFS was 11 months (95% CI, 8.2–13.7) and median PFS was 8 months (95% CI, 4.9–11).
Subgroup analyses for know clinical prognostic factors demonstrated prolonged OS in patients younger than 60 years and who
had KPS 100 and the PFS was signiﬁcant in KPS 100.
Conclusion. The use of carmustine wafers with radiation and concomitant and adjuvant TMZ does not appear to result in new
types of adverse events. A better outcome was seen in patients younger than 60 years and who had KPS 100.
http://dx.doi.org/10.1016/j.rpor.2013.03.129
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Introduction. Craniospinal irradiation is the standard treatment of some central nervous system tumors. The main difﬁculty of
this irradiation arises by the length of the region to be irradiated, which requires the use of several isocenters, with the problem
of the junction ﬁeld, the use of direct ﬁelds and source-surface distance (SSD) differently to standard.
Objective. Description of a radiotherapy planning technique for craniospinal irradiation that eliminates some of the problems of
conventional techniques.
Methods. We place the patient in prone position, with a thermoplastic mask and a vacuum mattress. The treatment planning
includes two or three isocenters (lumbar, thoracic and cervical). Initially lumbar isocenter is positioned at a 100 cm SSD, using
for this zone 3 beams (anteroposterior and 2 oblique). Then the isocenter cervical is positioned and ﬁnally dorsal isocenter by
anteroposterior ﬁeld, with the table and the collimator rotated to 90◦, following the divergence of the lumbar and brain beams.
Finally the brain area is treated by two opposing lateral beams, with collimator rotation. We made a direct treatment planning
by step-and-shoot, optimized by the algorithm of Pinnacle DMPO (own planning process of our Service).
Results. When we compared with standard techniques, less dose is administered in the abdominal area, increasing the dose in
the mouth, but within tolerable limits. The dose-volume histogram (HDV), are similar to the tomotherapy treatments.
Conclusions. Our craniospinal irradiation technique has some advantages of standard treatment and some disadvantages are
improved (dose reduction in risk organs, standard SSD),making it a relatively easy alternative to the completion and improvement
of this treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.130
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